Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

By Douglas B. Evans, G. Varadhachary, C. Crane, Charlotte C. Sun, Jeffrey E. Lee, P. Pisters, J. Vauthey, Huamin Wang, K. Cleary, G. Staerkel and 6 more. Journal of Clinical Oncology, 2008

721 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/e39f887569d3480a98c0b513a3a8d8ac4e1fcbc7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. A. Klein
2. Charles M. Perou
3. C. Der

Citations in the corpus

• A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma (2010, background): “This approach, in which patients who cannot tolerate the stress of therapy or who develop metastatic disease during treatment are spared surgery, has demonstrated an overall survival of 34 mo in this highly selected patient population [12,13].”
• Recent progress in pancreatic cancer (2013, background): “Neoadjuvant therapy should be considered in this patient population but is controversial, whereas patients with Stage III borderline resectable cancers should undergo neoadjuvant therapy prior to resection.(114) Patients with stage III locally advanced disease should be treated with chemotherapy and”